Buy Requip through the unique service that maximize your savings

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c41448) has announced the addition of the new Datamonitor report “Pipeline Insight: Parkinsons Disease And Restless Legs Syndrome - Reformulations Set To Drive Near-Term Growth” to their offering.
Despite affecting a large number of individuals, there are currently no treatments capable of curing either Parkinsons disease or Restless Legs Syndrome. Although available treatments are effective, numer…

Modest Market Growth Will be Driven by the Arrival of Once-Daily Formulations of Dopamine Agonists, According to a New Report from Decision Resources
WALTHAM, Mass., June 17 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory fi…

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c72211) has announced the addition of “Pipeline and Commercial Insight: Parkinsons Disease - Market to grow as first round of lifecycle management strategies” succeed to their offering.
Introduction
The PD market is set to con…

The results of two studies showing the potential utility of GlaxoSmithKline’s Requip (ropinirole) in the treatment of restless legs syndrome were presented at the Associated Professional Sleep Societies’ annual meeting in Chicago, USA. There are currently no medicine…

One of GlaxoSmithKline’s blockbuster replacement drugs is having approval problems Richard Hemming

Related Results

GSK faces approval delay.

…

FDA APPROVES REQUIP XL(TM), THE FIRST AND ONLY ORAL ONCE-DAILY
NON-ERGOT DOPAMINE AGONIST FOR PARKINSON’S DISEASE

Extended-Release Formulation Improved Symptoms in Patients Not
Optimally Controlled with Levodopa and Reduced Patients’”Off” Time by
Nearly Two Hours Per Day

LONDON, UK, 16 June 2008 — SkyePharma PLC (LSE: SKP) today announces
that the United States Food and Drug Administration (FDA)…

Requip XL Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients’ “Off” Time by Nearly Two Hours Per Day
RESEARCH TRIANGLE PARK, N.C., June 13 /PRNewswire-FirstCall/ — GlaxoSmithKline today announced the approval of Requip(R) XL(TM) (ropinirole extend…

Over a third of patients taking GlaxoSmithKline’s Requip (ropinirole HCl) for restless legs syndrome in clinical trials experienced significant improvement in their symptoms at one week, according to clinical trial results presented at the Associated Professional Sleep Societ…